Expert Roundtable: accelerating time to market for CAR-T cell therapies through translatable workflow

Cell & Gene Therapy Insights 2021; 7(10), 1379–1206


Published: 22 November 2021
Expert Roundtable Video
I Riviére, M Kurtoglu, T Haq

Isabelle Riviére

Director, Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center

Dr Rivière joined the faculty of the Memorial Sloan-Kettering Cancer Center (MSKCC) in 1999. She is currently the Director of the Cell Therapy and Cell Engineering Facility where she investigates novel strategies for cell therapies and immunotherapies to increase or retarget the immune response against tumors and treat hematological disorders. Her laboratory has developed multiple processes for clinical-grade gamma-retroviral and lentiviral vector production as well as hematopoietic and T-cell manufacturing.

Metin Kurtoglu

Chief GMP Manufacturing and Chief Medical Officer, Cartesian Therapeutics

Metin Kurtoglu, MD, PhD, is a medical oncologist board certified in internal medicine. Dr Kurtoglu’s clinical and basic science research career spans over 20 years and has focused on developing novel targets for drug-resistant cancer cells and cancer stem cells, including multiple myeloma. He has also been an investigator in various cancer immunotherapy trials. Cartesian Therapeutics is pioneering RNA cell therapies in and beyond oncology, with three assets in clinical trials for autoimmune, oncologic and respiratory disorders. The investigational therapies are manufactured at Cartesian’s cGMP manufacturing facility.

Tariq Haq

Head of Cell and Gene Therapy Segment Marketing at Lonza Bioscience Solutions

Tariq Haq is Head of Cell and Gene Therapy Segment Marketing at Lonza Bioscience Solutions. He brings with him extensive bioprocess experience including strategy development, new product launch and commercialization. Previously he has held positions in marketing and product management while working in companies such as Pall, GE Healthcare, Thermo Fisher Scientific and Millipore. He has authored publications in peer-reviewed journals such as Science and Vaccine. Tariq holds degrees in Physics and Biotechnology from Aligarh Muslim University in India and in Biochemistry from Texas A&M University in the US.